Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Aspen Pharmacare raises forecast after strong profit and cash‑flow increase
Aspen Pharmacare reports for FY 2026 a normalised headline earnings per share (NHEPS) of 802 cents (+28%), normalised EBITDA of 7.7 billion ZAR (+14%) and free cash flow of 3.8 billion ZAR. Despite largely stagnant revenue, profitability improved through margin increases, lower costs and restructuring effects; the stock rose to near a 52‑week high. Management forecasts for FY 2027 an EBITDA of at least 9 billion ZAR and NHEPS growth of over 50%, supported by strong GLP‑1 growth (including Mounjaro) and a recovery in sterile production. » More on de.investing.com
Aspen Pharmacare receives approval for Ozempic generic in Canada
Health Canada has approved Aspen‑Semaglutide, a generic semaglutide from Aspen Pharmacare for the treatment of type 2 diabetes. The drug is a generic version of Novo Nordisk’s Ozempic, made possible by the patent expiry on semaglutide. Market entry in Canada depends on the availability of the active ingredient from Dr. Reddy’s Laboratories. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 951.42M | - |
| Gross profit | 353.09M | - |
| Net profit | 62.83M | - |
| EBITDA | 173.95M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.08B |
Number of shares | 4.33M |
52-week high/low | €957.52 - €478.71 |
Dividend yield | 1.32% |
Dividends TTM | €0.13 |
Beta | 0.30 |
P/E ratio | 29.95 |
PEG ratio | -0.60 |
P/B ratio | 0.98 |
P/S ratio | 2.22 |
Company profile
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
| Name | Aspen Pharmacare |
| CEO | Stephen Bradley Saad |
| Headquarters | Durban,
nl South Africa |
| Website | |
| IPO | 01/04/2000 |
| Employees | 7,454 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Jnb | APN.JO |
Pnk | APNHF |
Frankfurt | LDZA.F |
DĂĽsseldorf | LDZA.DU |
MĂĽnchen | LDZA.MU |